Mrna vaccines against sars-cov-2: advantages and caveats
Fecha
2023Autor
Versión
Acceso abierto / Sarbide irekia
Tipo
Artículo / Artikulua
Versión
Versión publicada / Argitaratu den bertsioa
Identificador del proyecto
European Commission/Horizon 2020 Framework Programme/848166
ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119/ES/
ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010/ES/
ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069/ES/
Gobierno de Navarra//050-2019 Gobierno de Navarra//0011-1411-2020-000013 Gobierno de Navarra//0011-1411-2020-000033 Gobierno de Navarra//0011-1411-2019-000058
Impacto
|
10.3390/ijms24065944
Resumen
The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection
has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of
2021, millions of doses have been administered in several countries of North and South America
and Europe. Many studies have confirmed the efficacy of these vaccines in a wide range of ages
and in vulnerable groups of p ...
[++]
The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection
has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of
2021, millions of doses have been administered in several countries of North and South America
and Europe. Many studies have confirmed the efficacy of these vaccines in a wide range of ages
and in vulnerable groups of people against COVID-19. Nevertheless, the emergence and selection
of new variants have led to a progressive decay in vaccine efficacy. Pfizer–BioNTech and Moderna
developed updated bivalent vaccines—Comirnaty and Spikevax—to improve responses against the
SARS-CoV-2 Omicron variants. Frequent booster doses with monovalent or bivalent mRNA vaccines,
the emergence of some rare but serious adverse events and the activation of T-helper 17 responses
suggest the need for improved mRNA vaccine formulations or the use of other types of vaccines.
In this review, we discuss the advantages and limitations of mRNA vaccines targeting SARS-CoV-2
focusing on the most recent, related publications. [--]
Materias
BNT162b2,
Comirnaty,
MRNA vaccines,
MRNA-1273,
Myocarditis,
SARS-CoV-2,
Spikevax,
Th17 response,
Variants
Editor
MDPI
Publicado en
International Journal of Molecular Sciences, 2023, 24, 5944
Departamento
Universidad Pública de Navarra. Departamento de Ciencias de la Salud /
Nafarroako Unibertsitate Publikoa. Osasun Zientziak Saila
Versión del editor
Entidades Financiadoras
The OncoImmunology group is funded by the Spanish Association against Cancer (AECC, PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (FIS PI17/02119, FIS PI20/00010, COV20/00000, and TRANSPOCART ICI19/00069); a Biomedicine Project grant from the Department of Health of the Government of Navarre (BMED 050-2019); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848166.